Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Effect Of Lisinopril On Polycythemia
Sponsor: Mayo Clinic
Summary
The purpose of this study is to evaluate the effect of the (angiotensin-converting enzyme) ACE inhibitor lisinopril on hemoglobin, hematocrit, and erythropoietin levels in patients with secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis. This study aims to determine whether ACE inhibition can effectively reduce excessive erythrocytosis by modulating erythropoietin production.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-07-01
Completion Date
2029-07-01
Last Updated
2026-08-21
Healthy Volunteers
No
Conditions
Interventions
Lisinopril Tablets
Subjects will be treated with Lisinopril in three phases: Phase 1: Baseline-3 weeks: 2.5 mg dose Phase 2: Weeks 4 - 7: 5 mg dose (2 x 2.5mg tablets) Phase 3: Weeks 8-12: 10 mg dose (4 x 2.5 mg tablets)
Locations (2)
Mayo Clinic
Rochester, Minnesota, United States
St. Mary's Hospital
Rochester, Minnesota, United States